Supriya Lifescience Ltd.
Snapshot View

356.70 -8.50 ▼-2.3%

24 May 2022, 04:01:00 PM
Volume: 18,915

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.supriyalifescience.com
Market Cap 2,870.82 Cr.
Enterprise Value(EV) 2,664.21 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 18.86 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 18.91 Trailing Twelve Months Ending 2022-03
Industry PE 28.41 Trailing Twelve Months Ending 2022-03
Book Value / Share 76.50 Trailing Twelve Months Ending 2022-03
Price to Book Value 4.66 Calculated using Price: 356.70
Dividend Yield 0.17 Period Ending 2021-03
No. of Shares Subscribed 8.05 Cr. 80,482,800 Shares
FaceValue 2
Company Profile

The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.

The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA.

Business area of the company

The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Awards, accreditations or recognitions

  • 2009: Certificate of Excellence for outstanding Export Performance in the product group Chemicals, Drugs, Pharma and Allied Products (MSME) awarded by Federation of Indian Export Organisations.
  • 2010: Special Recognition National Award for Research and Development awarded by Ministry of Micro Small and Medium Enterprises, Government of India.
  • 2016: Export House for the Year for 2015-16 awarded by Directorate of Industries, Government of Maharashtra.
  • 2016: Export Achievement for 2015-16 in the product group Basic Chemical, Pharmaceutical & Cosmetics Products (MSME) awarded by Directorate of Industries, Government of Maharashtra.
  • 2017: Export House for the Year for 2016-17 awarded by Directorate of Industries, Government of Maharashtra
  • 2017: Export Achievement for 2016-17 in the product group Basic Chemical & Pharmaceutical Cosmetics (SSI) awarded by Directorate of Industries, Government of Maharashtra.
  • 2019: Outstanding Export Performance Award for the year 2018-19 for product group API / Bulk Drugs by Pharmaceuticals Export Promotion Council of India.

Major events and milestones

  • 2008 Incorporation of the Company upon its conversion from a partnership firm to a public limited company.
  • 2009: Started production of Ketamine Hydrochloride.
  • 2010: CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate.
  • 2011: IDL granted for Chlorphenamine Maleate.
  • 2013: COFEPRIS and KFDA approval granted.
  • 2014: USFDA approval granted
  • 2014: IDL granted for Brompheniramine Maleate.
  • 2015: EUGMP and EDQM approval granted.
  • 2017: CEP (Certificate of Sustainability) granted for Pheniramine Maleate.
  • 2017: Second time USFDA approval granted.
  • 2018: CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride.
  • 2020: Third time USFDA approval.
  • 2021: CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate.
  • 2021: NMPA approval granted.
  • 2021: Health Canada approval.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.33%
1 Week
-7.04%
1 Month
-16.59%
3 Month
-7.59%
6 Month
1 Year
2 Year
5 Year
10 Year
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 29.89 29.57 29.61 17.20 15.05 18.38 53.11 60.42 59.23
Return on Capital Employed (%) 21.78 19.43 15.83 12.27 11.48 13.80 36.52 49.67 60.12
Return on Assets (%) 5.30 5.42 5.37 2.80 2.40 3.59 15.82 24.90 31.66

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 26 30 37 42 46 55 94 149 269 616
Non Curr. Liab. 11 17 23 39 51 45 24 32 31 19
Curr. Liab. 65 83 115 150 144 146 135 155 146 100
Minority Int.
Equity & Liab. 101 130 176 231 241 245 253 336 446 735
Non Curr. Assets 39 52 73 102 126 126 120 138 179 237
Curr. Assets 62 78 103 129 115 120 133 198 266 498
Misc. Exp. not W/O
Total Assets 101 130 176 231 241 245 253 336 446 735

Profit Loss View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 78 92 113 138 171 184 213 278 312 385
Other Income 2 3 2 2 2 7 9 8 11 11
Total Income 80 95 115 140 173 191 222 286 323 396
Total Expenditure -68 -81 -98 -121 -151 -166 -191 -213 -213 -218
PBIDT 12 14 16 20 22 25 31 73 109 178
Interest -4 -5 -6 -7 -10 -12 -11 -10 -7 -4
Depreciation -1 -2 -2 -2 -4 -5 -5 -5 -6 -7
Taxation -2 -3 -2 -2 -2 -2 -6 -18 -23 -44
Exceptional Items
PAT 5 5 6 8 6 6 9 39 73 124
Adjusted EPS 14 10 13 17 4 4 6 27 50 17

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -6 14 27 28 49 116 80
Cash Fr. Inv. -23 -33 -27 -5 5 -25 -47
Cash Fr. Finan. 30 21 -2 -20 -50 -29 -15
Net Change 1 2 -2 3 4 62 18
Cash & Cash Eqvt 5 7 6 9 12 75 92

Shareholding Pattern View Details

2 Qtrs 2021-12 (%) 2022-03 (%)
Promoter 68.24 68.24
Public 31.76 31.76
Depository Receipts 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00

Announcements View Details

Mon, 23 May 2022
Statement Of Deviation Or Variation In The Use Of Proceeds Of The Fresh Issue Of The Initial Public Offer Of The Company
Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24 2019 please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended March 31 2022 in the prescribed format. Further we hereby confirm that there is no deviation or variation in the utilisation of IPO proceeds from the objects stated in the prospectus dated December 21 2021. Kindly take the same on record and acknowledge the receipt.
Mon, 23 May 2022
Audio Recording Of Earnings Call
In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the audio recording of the Companys Earnings Call held today (i.e. May 23 2022) regarding discussion on operational and financial performance for the Fourth Quarter and Financial Year ended March 31 2022 (Q4 and FY 2021-22) is available on the Companys website.The recording can be accessed from the link given below:https://supriyalifescience.com/investor-relation/financial/earning-call-recordings/ Kindly take the information on record.
Sat, 21 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
With reference to the above captioned subject please find enclosed newspaper advertisement published in Financial Express (English) and Loksatta (Marathi) on Saturday May 21 2022 containing Audited Financial Results for the quarter and year ended March 31 2022. You are requested to kindly take the same on record.

Technical Scans View Details

Tue, 24 May 2022
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Entering 52 Week Low Zone Close Entering 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,371.20 914.30 -0.8%
Divi's Laboratories Ltd. 97,215.92 3,662.05 -6.0%
Cipla Ltd. 78,341.65 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. 72,413.55 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. 52,337.62 3,640.00 -2.2%
Gland Pharma Ltd. 47,375.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. 44,015.42 2,601.25 -0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.04 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 32.84 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 31.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.18 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.18 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 39.10 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.11 2,601.25 -0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 3.76 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.77 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.46 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 6.62 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.81 2,601.25 -0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 0.10 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,601.25 -0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,601.25 -0.6%